Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun 6;8(1):8675.
doi: 10.1038/s41598-018-26629-5.

On the impact of different approaches to classify age-related macular degeneration: Results from the German AugUR study

Affiliations

On the impact of different approaches to classify age-related macular degeneration: Results from the German AugUR study

Caroline Brandl et al. Sci Rep. .

Abstract

While age-related macular degeneration (AMD) poses an important personal and public health burden, comparing epidemiological studies on AMD is hampered by differing approaches to classify AMD. In our AugUR study survey, recruiting residents from in/around Regensburg, Germany, aged 70+, we analyzed the AMD status derived from color fundus images applying two different classification systems. Based on 1,040 participants with gradable fundus images for at least one eye, we show that including individuals with only one gradable eye (n = 155) underestimates AMD prevalence and we provide a correction procedure. Bias-corrected and standardized to the Bavarian population, late AMD prevalence is 7.3% (95% confidence interval = [5.4; 9.4]). We find substantially different prevalence estimates for "early/intermediate AMD" depending on the classification system: 45.3% (95%-CI = [41.8; 48.7]) applying the Clinical Classification (early/intermediate AMD) or 17.1% (95%-CI = [14.6; 19.7]) applying the Three Continent AMD Consortium Severity Scale (mild/moderate/severe early AMD). We thus provide a first effort to grade AMD in a complete study with different classification systems, a first approach for bias-correction from individuals with only one gradable eye, and the first AMD prevalence estimates from a German elderly population. Our results underscore substantial differences for early/intermediate AMD prevalence estimates between classification systems and an urgent need for harmonization.

PubMed Disclaimer

Conflict of interest statement

Author H.H. has received lecture honorarium, travel support and is a member of the advisory board of the companies Bayer AG (Leverkusen, Germany), Allergan (Dublin, Ireland), and Novartis Pharma GmbH (Nürnberg, Germany). All other authors have no competing interests.

References

    1. Augood CA, et al. Prevalence of age-related maculopathy in older Europeans: the European Eye Study (EUREYE) Archives of ophthalmology. 2006;124:529–535. doi: 10.1001/archopht.124.4.529. - DOI - PubMed
    1. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet. 2012;379:1728–1738. doi: 10.1016/S0140-6736(12)60282-7. - DOI - PubMed
    1. Rosenfeld PJ, et al. Ranibizumab for neovascular age-related macular degeneration. The New England journal of medicine. 2006;355:1419–1431. doi: 10.1056/NEJMoa054481. - DOI - PubMed
    1. Rosenfeld PJ. Bevacizumab versus ranibizumab for AMD. The New England journal of medicine. 2011;364:1966–1967. doi: 10.1056/NEJMe1103334. - DOI - PubMed
    1. Klein R, et al. The Wisconsin age-related maculopathy grading system. Ophthalmology. 1991;98:1128–1134. doi: 10.1016/S0161-6420(91)32186-9. - DOI - PubMed

Publication types